At Bokhari Medical Consortium we offer Spravato treatment for Major Depressive Disorder and Treatment Resistant Depression (TRD). Spravato is the active ingredient in Esketamine; an approved drug by the Food and Drug Administration (FDA) for the use of an anesthetic.
Testimonials
ALLISON'S STORY
NICOLE'S STORY
Administered intranasally by the patient under supervision from a mental health professional in our facility over a two-hour span. Prior to treatment “Training” on the device is offered to ensure adequate administration since Spravato is a precisely measured drug.
Once the patient has decided to start treatment and one of our Board- Certified mental health professionals has approved the treatment of Spravato, the prior authorization through the patient’s insurance company will commence. (This step can be subjected to delays if the insurance information is not accurate on the benefit inquiry). Once the insurance company has approved to financially cover the office visit and medication, we will call in the prescription to the specialty pharmacy that is preferred by the patient’s insurance company.
For the first appointment, the patient should plan for more than the two-hour window normally needed. As protocol, the patient will start with a 56 mg dosage in order for them to acclimate to the prescription. Every appointment thereafter will have a dosage of 84mg, unless the mental health professional following the care has stated otherwise. During the administration of the drug, vitals are consistently monitored to ensure the safe and effective administration of the treatment. The patient administration of the treatment drug takes roughly 15 minutes, thereafter the patient will be monitored in one of our private rooms with our comfortable reclining treatment chairs. Patients are encouraged to bring noise-canceling headphones if they would like to sleep, or their electronic devices to pass the time with their favorite movie.
Our patient safety is our top priority, which is why they are monitored throughout this process and are required to find transportation assistance after each treatment session. The first. for 30 days, the patient will have two appointments a week, also known as the “induction phase.” After the first 30 days, the “maintenance phase” is started, which is once a week for thirty days. After these two phases are completed and the patient is feeling the therapeutic benefits, they are encouraged to make regular visits, on days of their choosing, to ensure that the therapeutic level doesn’t decrease. It is important to take all medication as prescribed during and after the phases of the treatment to ensure safe and effective results. According to clinical trials, patients who stayed on Spravato long-term, are less likely to experience relapse with their depressive symptoms. What better commitment than committing to yourself and your mental wellness!
Spravato FAQ
What is Spravato?
Spravato is a nasal spray medication containing esketamine, a derivative of ketamine. It is FDA-approved for the treatment of depression, particularly for individuals who haven't responded adequately to other antidepressant medications.
How does Spravato work?
Spravato works by influencing the glutamate system in the brain, which is different from traditional antidepressants. It is thought to help restore synaptic connections in the brain, leading to a rapid reduction in depressive symptoms.
Who is a suitable candidate for Spravato treatment?
Spravato is typically prescribed for individuals with treatment-resistant depression. It's crucial to consult with a healthcare professional to determine eligibility and assess the potential benefits and risks.
How is Spravato administered?
Spravato is administered as a nasal spray under the supervision of a healthcare provider. The initial dosing phase often involves more frequent administration, gradually transitioning to a maintenance phase.
What are the potential side effects of Spravato?
Common side effects may include dissociation, dizziness, and an increase in blood pressure. It's important to discuss potential side effects with your healthcare provider, who will closely monitor your response during and after each session.